Blue Note Therapeutics is a prescription digital therapeutics company singularly dedicated to helping patients live better. Blue Note is merging deep scientific and clinical expertise with digital and gaming ideas to transform care for seriously ill patients. Working closely with leading medical researchers and patient advocacy organizations, Blue Note is creating clinically validated, FDA-approvable, and prescription-only digital devices to treat the burden of illness. The company was founded in 2018 and is based in San Francisco, California.

HERINGS develops an AI Biostatistics Solution that facilitates efficient and low-risk clinical trials and an AI Clinical Research Platform that supports everything from product strategy and clinical trial design to data management and statistical analysis.

Cancer-related distress, which can be defined as any unpleasant feeling, emotion, or experience that affects a cancer patient’s quality of life or ability to cope with cancer diagnosis and treatment, affects millions of people. Fewer than half of those who experience cancer-related distress have access to the mental health care they need to find relief. Blue Note Therapeutics is working to close this gap.

We identify the exact pain points in current medical care system, prioritize them according to their significance and clinical implication, develop evidence based, science embedded solution algorithms, and implement them through our digital service platform.